Get the Stockscreener App
20.08
2.34%
0.46
After Hours:
20.08
Upstream Bio Inc stock is traded at $20.08, with a volume of 218.21K.
It is up +2.34% in the last 24 hours and up +14.29% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
See More
Previous Close:
$19.62
Open:
$19.79
24h Volume:
218.21K
Relative Volume:
0.46
Market Cap:
$1.08B
Revenue:
$2.22M
Net Income/Loss:
$-40.51M
P/E Ratio:
-15.63
EPS:
-1.2847
Net Cash Flow:
$-46.53M
1W Performance:
+5.85%
1M Performance:
+14.29%
6M Performance:
+172.46%
1Y Performance:
+0.00%
1-Day Range:
$19.56
$20.31
1-Week Range:
$18.18
$20.68
52-Week Range:
$5.14
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
20.08 | 1.06B | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
Upstream Bio Inc Stock (UPB) Latest News
What to do if you’re stuck in Upstream Bio Inc.July 2025 Technicals & Real-Time Volume Analysis Alerts - newser.com
How resilient is Upstream Bio Inc. stock in market downturnsQuarterly Profit Summary & Real-Time Buy Zone Alerts - newser.com
Will Upstream Bio Inc. stock outperform growth indexesFed Meeting & Technical Confirmation Alerts - newser.com
Is Upstream Bio Inc. stock trading at a premium valuationJuly 2025 Catalysts & Entry and Exit Point Strategies - newser.com
What earnings revisions data tells us about Upstream Bio Inc.2025 Earnings Surprises & Stepwise Trade Signal Implementation - newser.com
Can Upstream Bio Inc. stock sustain revenue growthMarket Activity Summary & Risk Controlled Swing Trade Alerts - newser.com
Upstream Bio's (UPB) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Will Rising Interest Rates Hurt Vintage Coffee and Beverages Limiteds Profit MarginsMonthly Performance Summary & Free Stop-Loss Planning for Your Portfolio - earlytimes.in
Measuring Upstream Bio Inc.’s beta against major indicesJuly 2025 News Drivers & Risk Adjusted Buy/Sell Alerts - newser.com
What does recent volatility data suggest for Upstream Bio Inc.Weekly Profit Analysis & Stepwise Entry and Exit Trade Signals - newser.com
What drives Upstream Bio Inc stock priceVolume Weighted Average Price & Plan Your Future With Strategic Investing - earlytimes.in
Visualizing Upstream Bio Inc. stock with heatmapsJuly 2025 Rallies & Technical Analysis for Trade Confirmation - newser.com
Can volume confirm reversal in Upstream Bio Inc.Trade Entry Report & AI Forecasted Entry/Exit Points - newser.com
Applying Elliott Wave Theory to Upstream Bio Inc.July 2025 Setups & Daily Stock Trend Watchlist - newser.com
Upstream Bio (UPB): Assessing Valuation as Shares Climb 7% Over the Past Week - Yahoo
Assessing Upstream Bio (UPB) Valuation After New Verekitug Phase 2 Data and Investor Interest Surge - Sahm
Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Why Upstream Bio (UPB) Is Up 14.0% After Positive Phase 2 Verekitug Data and Novel Dosing Approach - Sahm
News impact scoring models applied to Upstream Bio Inc.2025 Top Decliners & Safe Capital Growth Trade Ideas - newser.com
Is Upstream Bio Inc. forming a reversal patternJuly 2025 Update & Community Supported Trade Ideas - newser.com
Is Upstream Bio Inc. stock attractive for passive investorsMarket Growth Summary & AI Driven Stock Price Forecasts - newser.com
Earnings visualization tools for Upstream Bio Inc.July 2025 Earnings & Trade Opportunity Analysis - newser.com
Why retail investors pile into Upstream Bio Inc. stock2025 Market Outlook & Intraday High Probability Setup Alerts - newser.com
Upstream Bio Inc Stock Analysis and ForecastPrice Channel Trading & Free Popular Stock Picks Selection - earlytimes.in
Is Upstream Bio Inc. building a consolidation baseTrade Analysis Summary & Scalable Portfolio Growth Ideas - newser.com
Upstream Bio (NASDAQ:UPB) Trading 4.2% HigherStill a Buy? - MarketBeat
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress - The Manila Times
Upstream Bio Presents Data Showing Structural and - GlobeNewswire
24-Week TSLP Inhibition: Upstream Bio's Verekitug Shows Breakthrough Respiratory Disease Treatment Data - Stock Titan
Upstream Bio, Inc. $UPB Shares Sold by Goldman Sachs Group Inc. - Defense World
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Upstream Bio Inc Stock (UPB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Oct 15 '24 |
Buy |
17.00 |
825,000 |
14,025,000 |
4,554,873 |
| AI Upstream LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
1,175,000 |
19,975,000 |
1,175,000 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):